Skip to main content

Pablo Castillo Sánchez

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Pablo Castillo Sánchez

Institutions of which they are part

Research technician
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson's and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Maria Camprodon Gomez, Pablo Castillo Sánchez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 42000
Reference: 2024 PROD 00073
Duration: 02/12/2024 - 01/06/2026

NanoERT: nano-delivery platform for Enzyme Replacement Therapy in Parkinson´s and Gaucher's disease

IP: Marta Martínez Vicente
Collaborators: Mercedes Arrúe Gonzalo, Jorge Hernández Vara, Maria Camprodon Gomez, Jordi Riera Heredia, Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 24440
Reference: CI24-20222
Duration: 01/10/2024 - 30/09/2026

New nanotechnological therapy for Parkinson ?s disease: nose to brain delivery of GBA-polymer nanoconjugates

IP: Marta Martínez Vicente
Collaborators: Pablo Castillo Sánchez, Laia Perez Lasarte
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 73383.97
Reference: AGAUR/FI/2023/CASTILLO
Duration: 01/06/2023 - 31/05/2026

New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN)

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, New nanotechnological therapy for Parkinson's disease: nose-to-brain delivery of GBA-polymer nanoconjugates (NANOGBAtoBRAIN), Pablo Castillo Sánchez
Funding agency: Fundació "La Caixa"
Funding: 249950
Reference: HR22-00602
Duration: 01/11/2022 - 31/10/2025

Related news

The initiative seeks to raise awareness of the disease and promote the well-being of those affected, while fostering empathy and scientific vocations among young people.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

Related professionals

Luis Enrique Lara Moctezuma

Luis Enrique Lara Moctezuma

Kidney Physiopathology
Read more
Gerard Oristrell Santamaria

Gerard Oristrell Santamaria

Predoctoral researcher
Cardiovascular Diseases
Read more
Joaquin  Justel  Pizarro

Joaquin Justel Pizarro

Research technician
Clinical Neuroimmunology
Read more
Silvia Cabrera Diaz

Silvia Cabrera Diaz

Main researcher
Biomedical Research in Gynaecology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.